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ABSTRACT 
Healthcare organizations, governments and individuals have been forced by prevailing 
circumstances of economic crisis to be increasingly oriented towards cost containment due to 
escalating nature of health expenditure. 
Objective: 
The objective of this study is to determine the comparative cost effectiveness of various anti-
tuberculous therapeutic options and to make recommendation for the adoption of cost-
effectiveness evaluations in National Health Policy formulation and decision-making. 
Method  
Retrospective cost effectiveness analysis was carried out for prescribed/dispended antibiotic to 
outpatients with tuberculosis among other infectious diseases in outpatients case notes 
between 2005 and 2007 in Ahmadu Bello University Teaching Hospital, Zaria Nigeria. 
Results 
The result shows that ethambutol tablet cost N8.40/unit of effectiveness while streptomycin 
injection cost N81.50/unit of effectiveness in the treatment of tuberculosis.  Ethambutol tablet 
therefore appears to be more cost effective than streptomycin injection.  Subjecting the cost and 
effectiveness to sensitivity analysis did not change this conclusion.  Statistical analysis shows 
that there is a statistically significant difference in the effectiveness (outcome) of ethambutol 
(95%) and streptomycin injection (76.73%) (X2 =13.75; p<0.5).  Therefore there is association 
between effectiveness and therapeutic option chosen with ethambutol tablet being a more cost 
effective option.  The result of this study is significant because ethambutol is usually traded off 
for less cost-effective streptomycin in many cases even when there is no contraindication to the 
use of ethambutol. 
CONCLUSION 
Ethambutol tablet is more cost effective than streptomycin injection at their usual therapeutic 
doses in combination with isoniazed, rifampicin and pyrazinamide in the treatment of 
tuberculos1 at the intensive phase. 
KEYWORD:  Pharmacoeconomics, cost effectiveness analysis, ethambutol, streptomycin, 
tuberculoses.         
  
INTRODUCTION: 
Orientation towards cost containment 
due to escalating nature of health 
expenditure is continuously increasing.  
Only few data also exist regarding the 
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actual cost and benefits attributed to 
specific drug therapy in spite of 
widespread use of pharmaceuticals.  
This is probably due to lack of well-
defined methodologies to evaluate 
medical intervention.  Health sector 
allocation is increasing partly due to 
population growth and partly due to 
new health development.  This trend is 
not only observed in developed 
economy but also in developing ones 
like Nigeria where per 
capital income is low,  whereas this 
increase in expenditure does not 
necessarily translate into increase per 
head or access.(1)    
The health system is clearly in a state of 
rapid evolution.  Traditional 
approaches to healthcare decisions will 
no longer suffice, as they are not 
effective in curtailing cost objectively, 
therefore new tools need to be 
employed. 
Cost-effectiveness analysis, a form of 
pharmacoeconomic tool appears more 
effective if applied properly in 
therapeutic decision making.  The 
various outcome of therapy namely, 
economic, clinical and humanistic 
(psychosocial) outcomes are considered 
(1).  A comparative cost-effectiveness 
analysis was carried out for 
streptomycin and ethambutol in the 
treatment of tuberculosis in Ahamadu 
Bello University Teaching Hospital, 
Zaria, Nigeria. 
 
MATERIALS AND METHODS 
A retrospective study involving time 
and motion studies in conjunction with 
standard cost accounting techniques 
was carried out. 
Patients 
The study addressed adult outpatients 
in the Outpatients Department of 
Ahmadu Bello University Teaching 
Hospital, Zaria with tuberculosis 
among other infectious diseases 
confirmed by necessary diagnostic 
tools. (Table 3). 
Data Collection 
A total of 1018 outpatient case notes for 
tuberculosis were consecutively 
examined using diagnostic cards.  These 
are essentially diseases that have 
antibacterial agents as the  
 
mainstay of therapy. One hundred and 
ten (110) of the patients suffered from 
tuberculosis. 
A total of 1527 dispended prescription 
were sample systemically and 
examined.  Relevant information on 
prescribed/dispended drugs between 
the year 2005 and 2007 were extracted 
and recorded.  These included patient 
demographic data, diagnosis, 
concurrent illness, diagnostic test (if 
any), drug prescribed, dosage, duration 
of therapy, physician’s remarks on each 
visit and cost of drugs as well as 
treatment outcome. 
Computation of Data 
The cost per Defined Daily Dosage 
(DDD) of each antibacterial was 
calculated. DDD units are 
recommended by World Health 
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Organization (WHO) for analysis of 
drugs use.  DDD represents the usual 
dosage of an antibacterial per day (e.g 
Ampiclox 2g per day in 4 divided 
doses) (2). 
Cost-effectiveness Analysis 
Analysis of cost (in monetary units), 
and effectiveness in natural units 
(eradication of bacteria and clinical 
cure): 
Conduction of Cost-Effusiveness 
Analysis (3, 4 ) 
Definition of Pharmacoeconomic 
problem  
Should Option I be recommended or 
Option II (Table 3) as therapy of choice 
for the treatment of tuberculosis? 
Definition of the goal and objectives 
of problem situation 
The objective is to determine which of 
the treatment options provide greater 
value for money using effectiveness 
rating (table 4), decision analysis (Table 
3), cost of therapy (Table 6) and coast-
effectiveness analysis (table 7)   
 
Perspective 
Economic perspective of the health 
institution was chosen since the drugs 
were prescribed there.  However, 
patient perspective was considered 
where necessary 
a. Enumeration of the different 
ways to achieve the objective 
(Table 4) 
Consideration of valuable/ 
preferred treatment options. 
b. Determination of Costs of 
therapy 
Only direct medical costs were 
included in the analysis.  These 
include overhead and operating 
costs such as acquisition costs 
of the drugs.  Staff time (costs 
associated with preparation, 
dispensing, administration of 
product) where it differs from 
the two options considered.  
Others include equipment, 
disposa and transport costs to 
patient.  The cost per defined 
daily dosage (c/DDD) of each 
drug was used (Table 6) 
Time and motion studies was 
carried out for Pharmacists and 
Nurses that differed between 
each option.  There was no 
statistically significant 
difference between the 
frequency of physician visits 
among the two treatment 
options considered being 
outpatients.  The time and 
motion studies involved 
observing the actual work of 
each personnel.  This included 
the preparation and 
administration of injection and 
dispensing of tablets.  Each 
activity was timed using a 
stopwatch and the average time 
for 10 random observations for 
the completion of each of the 
tasks was determined.  The 
mean salary for the healthcare 
personnel was obtained from 
the accounts section of the 




Mean salary/sec =                   Annual  Salary 
   Hrs./wk x No. of wrks/annum x 360 
 
The individual costs were converted into cost per dosage regimen.
 
Discounting 
No adjustment for inflation or 
discounting was made for the analysis.  
Costs were fairly stable and both 
options were used within each year 
under review.  However, slight 
variation over the period of time 
required in some cases led to the use of 
mean cost of each option. 
Consequences (Outcomes) of each 
treatment option. 
The literature was reviewed for positive 
and negative outcomes of each 
treatment options (Table 4) (4-9)  
 
 
Sensitivity Analysis     
Sensitivity analysis was performed to 
test whether the decision changes when 
specific variables altered within 
reasonable range in favour of less cost 
effective option.  This was carried out 




Statistical analysis was carried out on 
the results obtained.  The effectiveness 
rating (percentage, proportion) was 
compared by the use of Chi-square 
analysis.              
 
RESULTS  
Table 1: COST EFFECTIVENESS ANALYSIS (CEA):- 
   Cost of therapy  Effectiveness (E)  CEA (C/E) 
Ethambutol  Tablet 400mg 
b.d. x 3/12 (Option I) 
 
N798.183 95 N8.40/Unit of 
effectiveness  
Streptomycin Inj. 1gm o.d. x 
3/12 (Option II)  
N6,253.80 76.73 N81.50/Unit 
effectiveness  
 
Using Ethambutol Tablet (option I) in 
combination with Isoniazid, Rifamficin 
and pytazinamide at the phase I 
(intensive phase) of Tuberculosis 
chemotherapy as a course of 400mg bid 
x 3/12 cost N798.12 with effectiveness 
measure of 95 and cost effectiveness of 
N8.40/unit of effectiveness while  
streptomycin injection as an alternative 
option at a course of 1gm o.d x 3/12 cost 
N6,253.80 with effectiveness measure of 
76.73 and cost effectiveness of 
N81.50/unit of effectiveness. 
 
Ethambutol tablet 400mg bid x 3/12 is 
therefore cheaper per unit of 
effectiveness than streptomycin 
injection  1gm o.d x 3/12 when used in 
combination with Isoniazed, Rifampicin 
and pyrazinamide in the Phase 




There is statically significant difference 
in the effectiveness (outcome) of 
ethambutol (95%) and streptomycin 
injection (76.73%) (X2 = 13.75; p<0.05). 
Therefore there is association between 
effectiveness and therapeutic option 
chosen. 
      
      Table 2: SENSITIVITY ANALYSIS  
S/NO ALTERATION IN VARIABLE COST EFFECTIVENESS 
1 Increasing the cost of Ethambutol  tablet by 300%  N33.61/Unit of effectiveness  
2 Increasing the effectiveness of streptomycin to 95% 
(Ethambutol value)   
N65.83/Unit of effectiveness  
3 Decreasing the cost of streptomycin by 50% N40.75%/Unit of effectiveness  
4 Decreasing Nurse’s preparation and administration 
time of streptomycin to 30 sec/day  
N66.60%/Unit of effectiveness  
 
Sensitivity analysis (what if analysis) 
indicates that the decision still remain 
valid as ethambutol is still more cost 
effective than streptomycin despite 
alterations made in favour of less cost 
effective Streptomycin.   
DISCUSSION 
Antimicrobial agents constitute the 
largest group of drug purchased in 
many countries and account for the 
highest proportion of drug budget 7,8, 
therefore efforts to ensure greater cost 
effectiveness is indispensable in view of 
limited resources.  Studies have shown 
that both ethambutol and streptomycin 
are predominantly used to prevent 
emergence of resistant strain of 
Mycobacterium tuberculosis, the causative 
agent of tuberculosis (7, 8, 9, 10)      
This justifies their inclusion in the 
intensive phase (Phase I) of treatment 
where either of them could be used 
based on cost and outcome of therapy 
(economic, clinical and humanistic) and 
individual patient peculiarity.  The use 
of streptomycin injection was found to 
be very rampant while ethambutol table 
is seldom used, even when there is no 
contraindication to its use in the study 
setting in spite of being more cost 
effective.  This result can be used as a 
tool to change the prescribing habit of 
doctors to a more rational one.  This is 
in agreement with the objective of 
pharmacoeconomic study that makes a 
person or a group changes their 
behaviour and persuade them hat a new 
course of action is a ‘better’ one.  ‘Better’ 
simply means in economic terms, it is 
more cost efficient 11. The result of this 
study agrees with the report of the 
British National Formulary that 
streptomycin is no longer popular as 
Phase I anti-tuberculous drug in many 
developing countries (12).  The 
statistically significant differences in the 
effectiveness of Ethambutol (95%) and 
Streptomycin injection (76.73%) (X2= 
13.75; p<0.05) could probably be due to 
differences in their economic clinical 
and humanistic outcomes7. 
Ethambutol tablet being an oral 
preparation  has no risk of infection, 
abscess or pain at the site of injection.  It 
therefore achieves 100% benefit of 
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safety of administration compared with 
average of 33.7% for streptomycin 
injection’s documented risk of infection 
(50%), risk of abscess (50%), pain at site of 
injection (99%) with only 1% likely to be free 
from pain 5,6,10. 
 
Table 3: Treatment Options for Cost- Effectiveness Analysis  
TREATMENT OPTION DISEASE  CONDITION DIAGNOSTIC TOOLS 
Option I  Option II 
Pulmonary Tuberculosis  Matoux test, AFB, X-ray, 
Microscopy, culture and 
sensitivity (m/c/s)    
Ethambutol tab 400mg bid 
3/12 in combination with  
Isoniazid, Rifampicin and 
Pyrazinamide   
Streptomycin inj 1gm o.d x 3/12 
in combination with  
Isoniazid, Rifampicin and 
Pyrazinamide   
 
Table 4:  Effectiveness Rating.  
VALUE STREPTOMYCIN INJ CRITERIA TABLET   ETHAMBUTOL 
  
VALUE  




   
Bacteriosatic with some reported 
bactericidal activity (intracellular)  
 
Both of them can achieve the desired 
therapeutic outcome is used effectively; 
100% sensitivity assumed.   
 
100% Bactericidal action; intracellular lack 
intracellular 5,6 (action).  It is effective in 
preventing the emergence of resistance 
to other anti-tuberculous drugs but add 
little if anything to the bactericidal and 
sterilizing action of Isoniazid, 




2.Pharmacokinetics  Oral absorption                  80%  
Pre-systemic metabolism    Nil 
Bioavailability                    80%  
Plasma t½                       10-15h 
Frequency of administration  o.d   
  80% Oral absorption not applicable  
Pre-systemic metabolism   (im) Nil 
Bioavailability (i.m inj.               100%  
Plasma t½              2.4-9.oh 







administration   
Risk infection                  nil 
Risk of abscess               nil 
Pain at site of injection    nil  
Tolerability                 100%  
100% Risk infection       50%} 
Risk of abscess                50%} 66.3%  
Pain at site of injection    99% 
Tolerability                 (100-66.3)% 
33.7% 
A  Adverse Drug 
Reaction (ADR) 
Dose dependent optic neuritis (easily 
reversible) at 15mg/kg<1% at 
25mg/kg<5%. 
Colour blindness Allergic rashes, 
Jaundice reported 
Tolerability   (100-5)%     
95% Ototoxic 5,6 progressive damage less 
reversible Vestibular  2.5% ditory lss 
common  
Hypersensitivity; very common 75% 
(can as well pharmacist and nurses for 
handling)  













 Table 5: Decision Analysis.  
TABLET ETHAMBUTOL 
(OPTION I)  
INJ STREPTOMYCIN  































2  Pharmacokinetics 80 0.2 16.0 100 0.2 2
0 
 




















4.Tolerability (100-DR)%   













Sum Of Criteria Ratings  - 1.0 95.0 - 1.00 76.7 
 
 
 COST OF THERAPY 
Only direct medical costs, were considered.  This include drug acquisition cost, costs associated 
with preparation, dispensing, administration and transport cost (to patient). 
 
TABLE 6: Duration of therapy:  Three months intensive phase (phase I) treatment.   
OPTION I  
ETHAMBUTOL TABLET  
OPTION II  
STREPTOMYCIN INJECTION  
Acquisition Cost = C/DDD x DOT in days = 400mg bid x 3/12   in 
days = 8.00 X 84 = N672.00 
 
Cost of dispensing by Pharmacist =   =0.2680 X 135 secs = N36.18  
Transport cost by patient (three monthly trips to refill 
prescription) 
 
N30/trip = N30 x 3 = 90.00  
Total = N798.18 
 
Acquisition Cost =1gm o.d x 3/12  = (C/DDD x DOT) = 25.0x84  
= 2,100= 
(N70/5gm vial, N10/needle & syr, N5/water for Inj)  
cost of preparation and administration by Nurses = 0.1945 x 100 
sec/day x 84 days =1,633.80 
Transport cost by patient (N30 per trip day) for injection a 
consideration) = N30 x 84 N2,520 
 





Table 7: Cost Effectiveness Analysis (CEA)    
OPTION I ETHAMBUTOL TABLET  OPTION II STREPTOMYCIN INJECTION 
Cost = N798.18,  Effectiveness = 95 
 
CEA = 798.18 = N8.40/Unit of effectiveness  
            95 
 
Cost = 6,253.80,  
Effectiveness = 76.73 
 
CEA = 6,253.80 =  
              78.8 
N81.50/unit of effectiveness  







Table 8 :SENSITIVITY ANALYSIS    
i.     Increasing cost of Ethambutol tablet by 300% (N3192.72) 
 
    CEA  3192.72   = N33.61 unit of effectiveness 
              95    
i.     Increasing the effectiveness of Streptomycin to 95% (Ethambutol value) 
 
    CEA  6253.80   = N65.83/unit of effectiveness 
                  95 
 
iii.     Decreasing cost of streptomycin  50% (N3126.90) 
 
    CEA  3126.90   = N40.75 unit of effectiveness 
              76.73 
 iv. Decreasing Nurses’ preparation and administration time of streptomycin  
injection to 30 sec/day instead of 100 sec/day.  This increases cost of therapy with streptomycin 
to N5110.14. 
 
    CEA  5110.14      N66.60/unit of effectiveness 
              76.73 
 
 
Sensitivity analysis (“what if’) indicates that the decision still remain valid, as 
Ethambutol is till more cost effective. 
 
This humanistic outcome enhances the 
effectiveness rating of Ethambutol tablet 
over Streptomycin injection.  
Ethambutol has also been reported to be 
tolerated in 95% of patie 
nts on it while Streptomycin injection’s 
tolerability is estimated to be 50%. 
This explains why individual patient 
peculiarity must be considered in choice 
of therapeutic option. For example, 
young children whose visual acuity can 
hardly be monitored objectively should 
not be given ethambutol.  Also in 
patient with optic neuritis.  The various 
adverse reaction of streptomycin, such 
as ototoxicity, nephrotoxicity, 
teratogenicity and hypertensivity 
reactions need to be considered as well. 
CONCLUSION AND 
RECOMMENDATIONS 
It is concluded that Ethambutol tablet at 
a course of 400mg bid x 3/12  is more 
cost effective than i.m streptomycin inj. 
1gm o.d. x 3/12, each in combination 
with isoniazid, rifampicin and 
pyrazinamide at the intensive phase 
(Phase I) of anti-tuberculous therapy. 
A very functional anti-tuberculous drug 
policy and evidence based treatment 
guidelines should be put in place if anti-
tuberculous drugs are to be used in a 
cost-effective manner. 
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